The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis

  21 March 2023

The increasing incidence of drug resistance in Mycobacterium tuberculosis has diminished the efficacy of almost all available antibiotics, complicating efforts to combat the spread of this global health burden. Alongside the development of new drugs, optimised drug combinations are needed to improve treatment success and prevent the further spread of antibiotic resistance. Typically, antibiotic resistance leads to reduced sensitivity, yet in some cases the evolution of drug resistance can lead to enhanced sensitivity to unrelated drugs. This phenomenon of collateral sensitivity is largely unexplored in M. tuberculosis but has the potential to identify alternative therapeutic strategies to combat drug-resistant strains that are unresponsive to current treatments. Here, by using drug susceptibility profiling, genomics and evolutionary studies we provide evidence for the existence of collateral drug sensitivities in an isogenic collection M. tuberculosis drug-resistant strains.

Further reading: Nature Communications
Author(s): Natalie J. E. Waller, Chen-Yi Cheung, Gregory M. Cook & Matthew B. McNeil
Effective Surveillance  


Unrestricted financial support by:


Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre


Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!


What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed